Intellia Therapeutics, Inc. (NTLA)
NTLA moved a median of -0.24% 30 minutes after news, and -0.04% by the close. How NTLA actually reacts to news — the realized, point-in-time move the market made, measured across 948 labeled events over the last three years with zero look-ahead.
NTLA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.26% | 40% | 942 |
| 30-min | -0.24% | 45% | 946 |
| 60-min | -0.33% | 44% | 946 |
| to close | -0.04% | 48% | 946 |
| Middle 50% of NTLA reactions | -1.58% to +0.94% |
|---|---|
| Median reaction (30-min) | -0.24% |
| Measured reactions | 948 |
Half of all Intellia Therapeutics, Inc. news events land between -1.58% and +0.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NTLA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 27 | -1.27% | 30% | -0.33% |
| Analyst downgrades | 38 | -2.02% | 37% | -2.30% |
| Rating reiterations | 147 | +0.06% | 54% | -0.38% |
| Price-target raises | 16 | +0.34% | 56% | -2.53% |
| Price-target cuts | 42 | -0.64% | 38% | -0.12% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how NTLA ranks against every other measured name →
That’s how NTLA usually reacts — get an email when it moves on news →Email me when NTLA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NTLA's baseline. Nothing else.
Recent NTLA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer | Press release | GlobeNewswire | +0.24% | -3.48% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.29% | +4.34% | |
| Form 8-K Intellia Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -2.32% | |
| Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) | Press release | GlobeNewswire | -1.64% | -0.70% | |
| Form 8-K Intellia Therapeutics, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | -0.70% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.64% | -0.70% | |
| Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | Press release | GlobeNewswire | +1.83% | +1.19% | |
| Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | +1.83% | +1.19% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.97% | — | |
| Form 10-Q Intellia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.63% | -0.33% | |
| Form 8-K Intellia Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.63% | +5.64% | |
| Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +2.63% | +5.64% | |
| Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +1.19% | +1.65% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.46% | -2.35% | |
| Form 8-K Intellia Therapeutics, For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +3.16% | +16.75% | |
| Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Press release | GlobeNewswire | +3.16% | +16.75% | |
| Form 8-K Intellia Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -2.30% | +1.40% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.48% | -2.46% | |
| Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 | Press release | GlobeNewswire | -0.80% | -0.22% | |
| Form 10-Q Intellia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.98% | +2.56% | |
| Form 8-K Intellia Therapeutics, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.98% | +2.56% | |
| Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +3.98% | +2.56% | |
| Intellia Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.44% | -5.60% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.88% | +4.21% | |
| Form 8-K Intellia Therapeutics, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +0.00% | |
| Form ARS Intellia Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.13% | +0.00% | |
| Form DEF 14A Intellia Therapeutics, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -1.13% | +0.00% | |
| Form DEFA14A Intellia Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.13% | +0.00% | |
| Intellia Therapeutics Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | +2.12% | +1.59% | |
| Form 8-K Intellia Therapeutics, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -2.39% | -8.36% | |
| Intellia Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +6.55% | +2.96% | |
| Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema | Press release | GlobeNewswire | -2.39% | -8.36% | |
| Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing | Press release | GlobeNewswire | -2.39% | -8.36% | |
| Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 | Press release | GlobeNewswire | -2.39% | -8.36% | |
| Form 8-K Intellia Therapeutics, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | +7.22% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.75% | +0.99% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.26% | +4.83% | |
| Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 | Press release | GlobeNewswire | -2.31% | -7.76% | |
| Form 8-K Intellia Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -2.28% | +12.05% | |
| Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | Press release | GlobeNewswire | -2.28% | +12.05% | |
| Form 10-K Intellia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.00% | -1.36% | |
| Form 8-K Intellia Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -7.85% | +1.49% | |
| Form S-8 Intellia Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.00% | -1.36% | |
| Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -7.85% | +1.49% | |
| Intellia Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.19% | +0.89% | |
| Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -0.33% | +6.80% | |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.67% | +8.48% | |
| Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine | Press release | GlobeNewswire | -2.07% | -7.68% | |
| Form 8-K Intellia Therapeutics, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | -9.79% | |
| Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN | Press release | GlobeNewswire | -2.31% | -9.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NTLA section they belong to.
Where else NTLA is measured.
NTLA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) | 951 | -0.14% | 41% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Biohaven Ltd. Common Shares (BHVN) | 944 | -0.27% | 45% |
| GW PHARMACEUTICALS PLC AMERICA (GWPH) | 942 | -0.06% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Intellia Therapeutics, Inc.'s median reaction calculated?
Every labeled NTLA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 948 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of NTLA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NTLA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.